Arthrogen BV was founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC) in Amsterdam. This biopharmaceutical company develops local gene therapy for inflammatory diseases, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases. Arthrogen’s aim is to develop gene therapies to deliver new alternatives to patients while decreasing healthcare costs.
exit per 17 december 2019